Cash first, science second
Verismo Therapeutics is getting a pretty meaningful $28 million boost from HLB Innovation, and in biotech that kind of check can feel like finding a spare battery in your backpack right when your phone hits 2%. The money is meant to keep the company’s KIR-CAR engine humming as it pushes two programs deeper into the clinic.
What’s getting the runway?
The funding is aimed at continued Phase 1 development of:
- SynKIR™-110, which is being studied in advanced solid tumors
- SynKIR™-310, which is being tested in B cell non-Hodgkin lymphoma
That matters because early-stage cancer trials are expensive, slow, and allergic to uncertainty. A strategic investment like this can stretch the runway, reduce financing anxiety, and make it easier to keep the trials on schedule.
The part investors will actually circle
Verismo also said initial clinical data from the STAR-101 Phase 1 trial of SynKIR™-110 will be presented at AACR 2026 on April 20. Translation: the market gets a near-term data checkpoint, and those readouts can be the difference between “interesting science project” and “okay, this might actually work.”
Big picture
For a clinical-stage biotech, fresh capital plus a coming data event is a decent one-two punch. You’re not buying certainty here — you’re buying more shots on goal, and in this game that’s often half the battle.